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Background
The secondary messenger cGMP does not only play an
important role in the cardiovascular system (vasodilation
and inhibition of platelet aggregation), but also regulates
the functions of numerous cell types like immune cells,
adipocytes or neurons [1,2]. Besides its inactivation by
phosphodiesterases, cGMP is exported from cells by the
organic anion transporter 2 (OAT2) [3] or by multi-
drug-resistance proteins (MRP) [4]. Thus, cGMP may
also cause effects from the extracellular side by acting as
a first messenger on cell surface receptors. In fact, extra-
cellular effects of cGMP have been described in the past.
A selection of papers is listed in Table 1. A more
detailed review is provided in [1].
Additionally, extracellular cGMP could be degraded by
ecto-phosphodiesterases and the degradation products
(GMP and guanosine) may have first messenger functions
of their own. In summary, the biological functions of
cGMP are much more versatile than previously acknowl-
edged. Therefore, our project aims at differentiating
between first- and second messenger functions of cGMP
and the other cyclic nucleotides (cNMPs) cAMP, cUMP
and cCMP in various cellular systems and functional
readouts.
Methods
The second messenger functions of cGMP were imitated
by the membrane-permeable acetoxymethyl ester analogue
(cGMP-AM), which releases cGMP after intracellular
hydrolysis. Unmodified cGMP was applied for the charac-
terization of extracellular first messenger effects. In a simi-
lar way, the first- and second messenger effects of cAMP,
cCMP and cUMP were characterized. As cellular models
and functional readouts we used (1) flow cytometric deter-
mination of apoptosis (annexin V/propidium iodide stain-
ing) of wildtype S49 lymphoma cells (S49 wt) and their
kinase-negative counterparts (S49 kin-), (2) flow cyto-
metric cell cycle determination of HEL (human erythro-
leukemia) cells, (3) ELISA-based quantitation of T-cell
receptor-mediated (anti-CD3 antibody stimulation) IL-2
production of HuT-78 lymphoma cells and (4) determina-
tion of chloride flux in Calu 3 lung epithelial cells with the
chloride-sensitive dye MQAE (N-(ethoxycarbonylmethyl)-
6-methoxyquinolinium bromide).
Results
None of the unmodified cyclic nucleotides (cAMP,
cGMP, cUMP, cCMP) caused apoptosis in S49 wt or
S49 kin- cells, and the cell-permeable AMs of cAMP,
cGMP and cUMP were not active either. Interestingly,
guanosine, a degradation product of cGMP, induced
apoptosis. Moreover, cCMP-AM exerted a surprising
pro-apoptotic effect on both S49 wt and S49 kin- cells.
Cell cycle analysis of HEL cells revealed that cGMP-AM
increased the percentage of cells in the SubG1 phase,
but reduced the proportion of cells in the G2/M phase.
The T cell receptor-mediated IL-2 production of
HuT-78 cells was inhibited by cGMP, but not by
cGMP-AM. The CFTR-mediated chloride flux in Calu 3
cells was slightly stimulated by cAMP-, cGMP- and
cUMP-AM, but cCMP-AM had no significant effect. No
significant stimulation of chloride flux in Calu 3 cells
was observed with cell-impermeable unmodified cNMPs.
Conclusions and outlook
Our data suggest that first and second messenger func-
tions of cGMP depend on cell type and functional readout.
Thus we plan to perform further studies with a variety of
model systems in order to generate a “functional profile”
of first- and second messenger effects of cGMP. Moreover,
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the surprisingly strong pro-apoptotic effect of cCMP-AM
on S49 cells warrants similar studies with cyclic pyrimi-
dine nucleotides. cCMP and cUMP now fulfil most of the
criteria for second messenger functions [5]. Finally, it was
recently reported that extracellular cIMP causes vasocon-
striction in porcine coronary arteries [6]. Thus, cIMP
should also be included in the list of potential first/second
messengers and characterized more closely in future
studies.
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rat model of colorectal pain analgesic (oral cGMP) [7]




glycine receptor-induced chloride current accelerates
desensitization
[10]
Schneider et al. BMC Pharmacology and Toxicology 2015, 16(Suppl 1):A84
http://www.biomedcentral.com/2050-6511/16/S1/A84
Page 2 of 2
